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Summary statement 
Stimulation of the ȕ2-adrenergic receptors appears to reduce lung fluid in 
patients with stable heart-failure.  
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ABSTRACT 
Introduction. The purpose of this study was to determine 1) if stable heart-
failure patients with reduced ejection fraction (HFrEF) have elevated 
extravascular lung water (EVLW) versus healthy control subjects, and 2) the 
HIIHFWRIDFXWHȕ2AR agonist inhalation on lung fluid balance. 
 
Methods. Twenty-two stable HFrEF patients and 18 age- and sex-matched 
healthy subjects were studied. Lung diffusing capacity for carbon monoxide 
(DLCO), alveolar-capillary conductance (DmCO), pulmonary capillary blood 
volume (Vc) (via rebreathe) and lung tissue volume (Vtis) (via computed 
tomography) were assessed before and within 30 min of administration of 
nebulized albuterol. EVLW was derived as Vtis ± Vc. 
 
Results. Pre-albuterol, Vtis and EVLW were greater in HFrEF vs. control (998 ± 
200 vs. 884 ± 123 ml, P = 0.041; 943 ± 202 vs. 802 ± 133 ml, P = 0.015, 
respectively). Albuterol decreased Vtis and EVLW in HFrEF í ± 7.8%, P = 
 í ± 8.8%, P = 0.018) DQG FRQWURO í ± 4.9%, P =  í ± 
5.7%, P = 0.045). There was an inverse relationship between pre-albuterol 
values and the pre- to post-albuterol change for EVLW (r2 = í0.264, P = 0.015) 
and DmCO (r2 = í0.343, P = 0.004) in HFrEF only. 
 
Conclusion. Lung fluid is elevated in stable HFrEF patients relative to healthy 
subjects. Stimulation of the ȕ2ARs may cause fluid removal in HFrEF, especially 
in patients who exhibit greater evidence for increased lung water at baseline.  
 
Key words: pulmonary edema, albuterol, lung diffusing capacity, computed 
tomography. 
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INTRODUCTION 
Chronic heart failure (HF) is associated with an increase in pulmonary capillary 
pressure and wall tension secondary to the rise in left ventricle (LV) filling 
pressure consistent with a failing LV (1). Additionally, it has been shown that a 
chronic increase in adrenergic drive, as occurs with HF, elicits a down-regulation 
of the ȕ UHFHSWRUV central to lung fluid removal mechanisms (2-4). In 
combination, it is possible that the aforementioned changes in the pulmonary 
system associated with HF may conspire to increase fluid flux across the 
pulmonary vasculature while impairing fluid clearance from the alveoli and 
interstitial space, thus making HF patients more susceptible lung fluid 
accumulation relative to their healthy counterparts. While pulmonary congestion, 
a key component of which is a significant increase in lung fluid, is a hallmark of 
acute decompensation in heart failure (5-7), whether stable HF patients exhibit 
increased extravascular lung fluid remains controversial with some (8) but not all 
(9) reporting an increase in lung water content in HF patients. Moreover, the role 
of alterations in lung ȕ-adrenoreceptor system mediated fluid clearance 
mechanisms in the pulmonary edema associated with HF is unclear. 
Accordingly, in the present study we aimed to determine 1) whether stable HF 
patients with reduced ejection fraction (HFrEF) have elevated lung fluid 
compared to their healthy age and sex matched counterparts, and 2) the effect of 
an acute inhaled ȕ2-adrenergic receptor agonist on lung fluid balance in stable 
HFrEF patients.  
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MATERIALS AND METHODS 
Participants and ethical approval 
Twenty-two adult patients with a history of heart failure with reduced ejection 
fraction (HFrEF) and 18 healthy age- and sex-matched controls volunteered to 
participate in the study (Table 1). The patients recruited for the study were 
UHTXLUHGWRPHHWWKHIROORZLQJFULWHULD\KLVWRU\RINQRZQ+F, 2) ejection 
IUDFWLRQRI%, 3) New York Heart Association (NYHA) functional class I, II 
or III, 4) stable symptoms (i.e. receiving optimal medication and have had no 
change in disease status or medication) for >3 months, 5) free of uncontrolled 
systemic hypertension, anemia, or other comorbidities (e.g., COPD), 6) not 
pacemaker dependent, and 7) a BMI <36. The age-matched controls were 
recruited from the surrounding community and were current nonsmokers (past 
15 years) with no history of cardiac or pulmonary disease. Each participant gave 
written informed consent after being provided a detailed description of the study 
requirements. The experimental procedures were approved by the Mayo Clinic 
Institutional Review Board and were performed in accordance with the 
Declaration of Helsinki. 
 
Experimental procedures 
The experimental procedures were conducted during two separate laboratory 
visits separated by no longer than 1 week. At the first visit, complete blood count 
was assessed to rule out anemia before pulmonary function was assessed via 
body plethysmography (MedGraphics Elite Series Plethysmograph, Medical 
Graphics Corporation, St. Paul, MN, USA) according to standard procedures 
5 
 
(10). During the second session, albuterol, a short acting ȕ2-adrenergic receptor 
agonist, was administered at a dilution of 2.5 mg per 3 ml of saline using a 
nebulizer for 15 minutes in each participant. Pulmonary function, lung diffusing 
capacity for carbon monoxide (DLCO) and nitric oxide (DLNO), alveolar-
capillary membrane conductance (DmCO) and pulmonary capillary blood volume 
(Vc) were assessed before and within 30 min after albuterol administration. 
Similarly, lung density and lung tissue volume (Vtis) were measured before and 
within 30 min post-albuterol via chest CT imaging.  
 
Lung diffusing capacity  
DLCO, DLNO, DmCO and Vc were assessed by simultaneously measuring the 
disappearance of CO and NO using a rebreathe technique, as we have described 
previously (11, 12). Participants sat upright and breathed through a two-way 
switching valve that was connected to a pneumotachometer, a mass spectrometer 
(Marquette 1100 Medical Gas Analyzer, Perkin-Elmer, St. Louis, MO) and a NO 
analyzer (Sievers 280i NOA, Sievers, Boulder, CO). The inspiratory port of the 
switching valve was set to either room air or a 5-L anesthesia bag filled with 
0.3% CO (C18O), 40 parts per million (ppm) NO (diluted in the bag immediately 
before each rebreathe maneuver from an 800 ppm gas mixture), 35% O2 and N2 
balance. The total volume of gas in the anesthesia bag was determined by the 
resting tidal volume of each participant. For each rebreathe maneuver, the 
participants breathed normally on room air for 4-5 breaths before, at the end of a 
normal expiration, they were VZLWFKHG WR WKH UHEUHDWKHEDJDQG WROG WR³QHDUO\
HPSW\WKHEDJ´ZLWKHDFKLQVSLUDWLRQIRU-12 consecutive breaths at a breathing 
frequency of 32 breaths per min. Each participant performed the rebreathe 
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maneuver in triplicate before and within 30 min after administration of nebulized 
albuterol. DLCO, DLNO, DmCO and Vc were computed using custom analysis 
software.  
 
Lung tissue volume & lung density via computed tomography 
All CT scans were performed using the same scanner (GE LiteSpeed Spiral CT 
Scanner, GE Healthcare). Initial slices obtained for all scans were 2.5 mm thick 
with a 1.2 mm overlap and were then reconstructed to 1.25 mm thick with a 0.6 
mm overlap. Prior to the baseline scan (i.e. pre-albuterol administration) a scout 
scan was performed to determine the location and size of the lungs. The 
anatomical location at the start of the scan was marked on each subject using 
indelible ink and the table height, field of view and the number of images 
obtained were recorded to ensure consistency between the CT scans taken pre- 
and post-albuterol administration. For each CT scan, the participants were 
instructed to breathe normally before inspiring fully and performing a breath-
hold at total lung capacity (TLC) before the scan was initiated. During each scan, 
the participants breathed through a mouthpiece connected to a 
pneumotachometer that was integrated with a portable computer with custom 
analysis software so that accurate lung volumes could be measured; this protocol 
ensured that all pre- and post-albuterol CT measures of lung tissue volume and 
lung density were made at the same lung volume.   
 
For analysis, the CT images were submitted to image analysis software 
(Pulmonary Analysis Software Suite, Physiological Imaging Laboratory, 
University of Iowa, Iowa City, IA) and all analyses were performed by a single 
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member of the research team who was blinded to the condition (i.e. pre- or post-
albuterol) of each CT scan. First, the Pulmonary Analysis Software was used to 
segment the images to separate lung tissue from surrounding structures and the 
mediastinum for analysis of parenchymal attenuation. In each picture element 
lung density was assumed to be a linear combination of air and lung tissue, 
which have an DWWHQXDWLRQRIí and 0 Hounsfield units (HU), respectively. 
A histogram analysis of picture elements within the lung tissue was performed to 
obtain mean lung density in HU and tissue volume by summation of each voxel 
among all elements in the lung fields.  
 
Estimation of extravascular lung water  
The parenchymal attenuation assessed by CT (i.e. tissue volume, Vtis) includes 
lung tissue, blood and water. By combining our CT derived measure of tissue 
volume and our measure of Vc from the lung diffusing capacity maneuvers (12), 
we were able to estimate the volume of extravascular lung water (EVLW) as:  
EVLW = Vtis ± Vc 
where, EVLW is extravascular lung water in ml, Vtis is tissue volume in ml 
determined via CT, and Vc is pulmonary capillary blood volume in ml assessed 
via our CO and NO rebreathe technique.  
 
Albuterol administration 
Using a nebulizer, albuterol (DVKRUWDFWLQJȕ2-AR agonist) was administered at a 
dilution of 2.5 mg/3ml of saline for ~15 min during tidal breathing in each 
participant. Heart rate (HR) and cardiac rhythm were measured via a 12-lead 
ECG throughout albuterol administration. Similarly, arterial oxygen saturation 
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(SaO2) was monitored continuously during albuterol administration using a pulse 
oximeter (Nellcor N-595, Tyco Healthcare Group, Nellcor Puritan Bennett 
Division, Pleasanton, CA, USA) and a forehead sensor. Manual blood pressure 
and the rating of perceived dyspnea were obtained before albuterol 
administration and at two minute intervals thereafter until 5 min post-albuterol.  
 
Statistical analyses 
Independent samples t-test was used to compare subject characteristics, measures 
of lung function and absolute measures of lung diffusion capacity and related 
variables, CT derived lung density and lung tissue volume, and extravascular 
lung water at equivalent time-points between the experimental groups (control 
vs. HFrEF). Paired samples t-test was used to compare absolute measures of lung 
diffusion capacity and related variables, CT derived lung density and lung tissue 
volume, and extravascular lung water across time (pre- vs. post-albuterol 
administration) within each experimental group (control and HFrEF). Pearson 
product-moment correlation coefficient (r) was computed to assess the 
relationships between baseline (i.e. pre-albuterol) measures of lung tissue 
volume, extravascular lung water and alveolar-capillary membrane conductance 
relative to pulmonary capillary blood volume and the change in these variables 
from before to after albuterol administration in control subjects and HFrEF 
patients. The acceptable type I error was set at P < 0.05. Results are expressed as 
means ± SD unless otherwise stated. Statistical analysis was performed using 
SPSS version 21.0 for Windows (SPSS, Chicago, IL).     
 
RESULTS 
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Participant characteristics and pulmonary function measurements are shown in 
Table 1.  
 
Lung fluid balance in HFrEF vs. healthy control subjects 
Baseline pre-albuterol measures of DLCO, DmCO, Vc, lung density, Vtis, and 
EVLW are shown in Table 2. Pre-albuterol administration, group mean DLCO 
(P = 0.037) and Vc (P = 0.003) were greater in control subjects compared HFrEF 
patients; there was no such difference in DmCO between subject groups (Table 
2). Baseline pre-albuterol group mean lung density (P < 0.001), Vtis (P = 0.041) 
and EVLW (P = 0.015) were greater in HFrEF patients compared to healthy 
control subjects (Table 2). These data suggest that lung fluid is elevated in stable 
HFrEF patients relative to healthy subjects. 
 
Effect of ȕ2-AR stimulation in HFrEF and healthy controls  
There was little/no change in either HR or blood pressure from before to 
immediately after albuterol administration in the HFrEF patients (HR 65 ± 9 vs. 
69 ± 11 bpm, P = 0.129; MAP 92 ± 8 vs. 95 ± 7 mmHg, P = 0.098). Similarly, 
no evidence of cardiac arrhythmia was observed in any participant during 
albuterol administration. Albuterol administration had no effect on FVC, but 
caused an increase in FEV1, FEF25-75% and IC in both the control subjects and 
HFrEF patients (Table 3). DLCO, DmCO, Vc and DmCO/Vc were not different 
from before to after albuterol administration in neither the control subjects nor 
the HFrEF patients (Figure 1). Albuterol administration did, however, cause a 
significant reduction in Vtis in both the healthy control subjects and the HFrEF 
SDWLHQWVFRQWUROíP = 0.029; HFrEFíP =0.010) (Figure 
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2). Similarly, there was a significant reduction in EVLW from before to after 
albuterol administration in both the control subjects and the HFrEF patients 
(control: í3.0 ± 5.7%, P = 0.045; HFrEF íP = 0.018) (Figure 2). 
There was a trend towards an inverse relationship between baseline values of 
Vtis, EVLW and DmCO/Vc ratio and the magnitude of the change in these 
variables from before to after albuterol in both the control subjects and the 
HFrEF patients; however, these relationships were statistically significant for 
EVLW and DmCO/Vc ratio in the HFrEF patients only (Figure 3). These data 
may suggest that stimulation of the ȕ2-ARs via nebulized albuterol 
administration promoted a greater degree of lung fluid clearance in individuals 
with the greatest evidence lung fluid at baseline.  
 
DISCUSSION 
Main findings 
The main findings of the present study were: 1) before albuterol administration, 
lung density, lung tissue volume (Vtis) and extravascular lung water (EVLW) 
were greater in the HFrEF patients compared to the healthy control subjects, 2) 
lung diffusing capacity for carbon monoxide (DLCO) and pulmonary capillary 
blood volume (Vc) were greater in control subjects compared to the HFrEF 
patients before albuterol administration, 3) albuterol administration caused a ~3 
to 5% reduction in Vtis and EVLW in healthy control subjects and HFrEF 
patients, and 4) there was a trend towards an inverse relationship between 
baseline values of Vtis, EVLW and DmCO/Vc ratio and the magnitude of the 
change in these variables from before to after albuterol in both the control 
subjects and the HFrEF patients; however, this relationship was statistically 
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significant for EVLW and DmCO/Vc ratio in the HFrEF patients only. In 
combination, the findings of the present study suggest that 1) lung fluid volume 
is elevated in stable, well compensated HFrEF patients relative to their healthy 
age and sex matched counterparts, and 2) acute stimulation of the ȕ2-ARs 
appears to cause lung fluid removal in stable HFrEF patients, especially in 
patients with evidence of elevated lung fluid volume at rest. Our study 
demonstrates that pharmacological stimulation of the ȕ2-ARs may help reduce 
lung fluid volume in stable HFrEF patients, and thus lends support to the 
hypothesis that ȕ2-ARs play an important role in lung fluid balance in vivo in 
humans and that dysfunction of the ȕ2-ARs may be a source of elevated lung 
fluid volume in stable heart failure patients.  
 
7KHLPSRUWDQFHRIWKHȕ2-AR system in the control of fluid balance 
7KH ȕ2-ARs are expressed throughout the pulmonary system, including in the 
airways, the alveolar spaces, the pulmonary vasculature and the pulmonary 
lymphatic tissue, where they appear to regulate lung fluid removal via two 
distinct mechanisms. First, it appears that VWLPXODWLRQ RI WKH ȕ2-ARs facilitates 
fluid removal from the alveolar spaces through epithelial sodium channels 
(ENaC) located on both type I and type II alveolar cells (13, 14). Indeed, it has 
been shown previously that stimulation of the ȕ2-ARs is associated with an 
increase in both the total number and open probability of ENaC on the apical 
portion of type I and type II alveolar cells secondary to an increase in the 
synthesis of cyclic adenosine monophosphate (cAMP) and protein kinase A 
(PKA) (13). Second, it has been shown that stimulation of the ȕ2-ARs on 
lymphatic tissue causes dilation as well as active phasic contraction of the 
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thoracic lymphatic ducts, which acts to clear lung fluid from the perivascular 
spaces to the hilar lymph nodes (15, 16). 
 
The importance of the ȕ2-AR system in the regulation of lung fluid in both 
animal models and in humans has been demonstrated through a number of key 
studies (17-26). For example, Tibayan et al (22) reported that administration of 
the QRQVHOHFWLYHȕ1 DQGȕ2 UHFHSWRUDJRQLVWGREXWDPLQHEXWQRWWKHVHOHFWLYHȕ1 
agonist dopamine, caused a substantial increase in alveolar liquid clearance 
(~50%) in anesthetized ventilated rats. In addition, it has been shown that 
DOYHRODU ȕ2-$5 RYHUH[SUHVVLRQ LPSURYHV ȕ2-AR function and maximally 
upregulates alveolar fluid clearance in a rat model (21, 23). In vivo in humans, it 
KDV EHHQ GHPRQVWUDWHG WKDW DGPLQLVWUDWLRQ RI WKH ORQJ DFWLQJ ȕ2-AR agonist 
salmeterol results in a ~50% decrease in the incidence of high-altitude 
pulmonary edema (HAPE) in subjects identified as HAPE susceptible (18). More 
recently, it has been shown that RUDODGPLQLVWUDWLRQRIWKHQRQVHOHFWLYHȕ1 DQGȕ2 
receptor blocker CarvediloOEXWQRWWKHVHOHFWLYHȕ1 blocker Bisoprolol, caused a 
significant decrease (~13%) in alveolar-capillary membrane conductance in 
healthy humans, which is indicative of an increase in extravascular lung water 
(17). In combination, the findings detailed above clearly identify the key role of 
the ȕ2-AR system in the regulation lung fluid balance and in the maintenance of 
lung fluid homeostasis. In addition to the aforementioned findings, in the present 
study ZHIRXQGWKDWDFXWHDGPLQLVWUDWLRQRIWKHVHOHFWLYHȕ2-AR agonist albuterol 
caused a significant reduction in lung tissue volume and extravascular lung water 
(~3-5%) in both stable HFrEF patients and healthy control subjects (Figure 2). In 
addition, there was a trend towards an inverse relationship between baseline 
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values of Vtis, EVLW and DmCO/Vc ratio and the magnitude of the change in 
these variables from before to after albuterol in both the control subjects and the 
HFrEF patients; however, this relationship was statistically significant for 
EVLW and DmCO/Vc ratio in the HFrEF patients only. These data suggest 
perhaps suggest that the greatest lung fluid clearance in response to acute 
albuterol administration occurs in the HFrEF patients who exhibit the greatest 
degree of lung fluid volume at rest. Accordingly, our study demonstrates that 
acute pharmacological stimulation of the ȕ2-ARs reduces lung fluid volume in 
both stable HFrEF patients and healthy control subjects, and thus lends support 
to the hypothesis that 1) ȕ2-ARs play a vital role in lung fluid balance in vivo in 
humans, and 2) that dysfunction of the ȕ2-ARs may be a source of elevated lung 
fluid volume in stable HFrEF patients.  
 
Why is lung fluid increased in stable HF? 
It is well known that pulmonary congestion, a key component of which is a 
significant increase in lung fluid, is a common consequence of acute 
decompensation in HF (5-7). However, it has remained somewhat controversial 
whether stable HF patients exhibit elevated lung fluid volume (8, 9), with 
FKURQLF+)SDWLHQWVRIWHQDSSHDULQJWR³UHVLVW´SXOPRQDU\HGHPD (24). Indeed, in 
clinical practice it is often observed that patients with severe HF lack pulmonary 
rales on examination or alveolar edema on chest x-ray. Theoretically, the 
increase in pulmonary capillary hydrostatic pressure and wall tension due to the 
rise in LV filling pressure consistent with a failing LV (1) combined with down-
UHJXODWLRQRI WKHȕUHFHSWRUV WKDWDUHFHQWUDO WR OXQJIOXLGUHPRYDOPHFKDQLVPV 
(2-4) secondary to a chronic increase in adrenergic drive should serve to make 
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HF patients more susceptible to lung fluid accumulation relative to their healthy 
counterparts. However, it has also been shown that pulmonary microvascular 
permeability is decreased in severe HF patients, which would be expected to 
protect such patients from pulmonary edema (24). Presently, we found that lung 
fluid is elevated in stable HFrEF patients relative to healthy subjects (Table 2). 
These data perhaps suggest that, while somewhat preventative, the reduction in 
pulmonary microvascular permeability often observed in stable HFrEF patients 
does not fully protect against an increase in extravascular lung water in this 
population. 
 
Clinical implications 
Recently, we have reported that CT derived measures of large airway wall 
thickness and luminal area are not different in healthy control subjects relative to 
stable HFrEF patients (27). In combination with the findings of the present 
study, data from our laboratory suggest that stable, well compensated HFrEF 
patients have evidence of elevated lung fluid volume but not substantial large 
airway edema and/or engorgement relative to their healthy age and sex matched 
counterparts. Although the exact clinical ramifications of such an accumulation 
of lung fluid in these patients are unclear, it is possible that interstitial lung 
edema plays a role in abnormal pulmonary gas exchange and exaggerated 
ventilatory response to exercise associated with HF. HF is of course a complex 
disease and much of the impaired pulmonary gas exchange and hyperventilatory 
response to exercise in HF patients has been associated with pulmonary vascular 
dysfunction (28, 29), skeletal muscle dysfunction (30, 31), early onset of 
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metabolic acidosis (32), heightened chemosensitivity, and exaggerated afferent 
signals from exercising muscles (30). However, in animal models, it has been 
demonstrated that artificial induction of pulmonary congestion causes a rapid 
shallow breathing pattern secondary to stimulation of pulmonary C-fibers (33). 
In addition, acute fluid loading in otherwise healthy humans has been shown to 
elicit a less efficient hyperventilatory response to incremental exercise (34). 
Indeed, Robertson et al. (34) reported that rapid intravenous saline infusion (30 
mL/kg over 30 min) caused a ~12% and ~4% increase in extravascular fluid and 
intravascular fluid, respectively, with a concomitant ~12% increase in the 
ventilatory equivalent for carbon dioxide as well as a slight decrease in arterial 
PCO2 and a reduction aerobic exercise capacity. . More recently, Paolillo et al 
(17) found that administration of the ȕ2-AR antagonist Carvedilol caused a ~12% 
increase in WKH9%cE9%c&22 slope in response to exercise that was always coincident 
with a ~13% decrease in DmCO (i.e. evidence of an increase in lung interstitial 
fluid volume). Based on the aforementioned considerations, it possible that lung 
interstitial edema provides an additional stimulus for the impaired pulmonary gas 
exchange and the inefficient hyperventilatory response to exercise commonly 
observed in HF patients. Moreover, given that a low DmCODQGDKLJK9%cE9%c&22 
(slope or ratio) are key prognostic predictors in HFrEF patients (35, 36), it can 
be suggested that elevated extravascular lung water may represent an important 
target for therapeutic intervention in these patients. In the present study we found 
that acute low-dose albuterol administration appears to cause lung fluid 
clearance (~5%) in stable HFrEF patients. Whether such acute pharmacological 
stimulation of the ȕ2-ARs may be indicated in the presence of clinical and/or 
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radiological signs of pulmonary edema in stable HFrEF patients requires further 
investigation.   
 
Conclusion 
In conclusion, lung fluid volume is elevated in stable, well compensated heart 
failure patients with reduced ejection fraction relative to their healthy age and 
sex matched counterparts. Interestingly, stimulation of the ȕ2-adrenergic 
receptors via acute low dose nebulized albuterol appears to promote lung fluid 
removal in both healthy control subjects and heart failure patients, but especially 
in HFrEF patients who exhibit evidence of elevated lung water at rest. Whether 
such acute ȕ2-adrenergic receptor stimulation may provide a therapeutic aid to 
the excessive lung fluid commonly observed in HFrEF requires further 
investigation. 
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FIGURE LEGENDS 
Figure 1. Group mean ± SD lung density lung diffusing capacity for 
carbon monoxide (DLCO) (A), alveolar capillary membrane 
conductance (DmCO) (B), pulmonary capillary blood volume (Vc) (C) 
and the ratio of DmCO to Vc (DmCO/Vc) (D) before (pre-albuterol; 
white bars) and after (post-albuterol; black bars) nebulized albuterol 
administration in healthy control subjects (Control) and heart failure 
patients with reduced ejection fraction (HFrEF).  
 
 
Figure 1.  
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Figure 2. Group mean ± SD lung density (A), lung tissue volume 
(Vtis) (B) and extravascular lung water (EVLW) (C) before (pre-
albuterol; white bars) and after (post-albuterol; black bars) nebulized 
albuterol administration in healthy control subjects (Control) and heart 
failure patients with reduced ejection fraction (HFrEF). *P < 0.05, **P 
< 0.01; value significantly different vs. pre-albuterol.  
 
Figure 2.  
 
  
22 
 
Figure 3. Scatter plots showing the relationships between the 
individual subject baseline values (i.e. before nebulized albuterol 
administration) and the before to after nebulized albuterol change in 
lung tissue volume (Vtis) (A & B), extravascular lung water (EVLW 
(C & D) and the ratio of alveolar capillary membrane conductance to 
pulmonary capillary blood volume (DmCO/Vc) (E & F) in in healthy 
control subjects (open circles) and heart failure patients with reduced 
ejection fraction (closed circles).  
 
Figure 3.  
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Table 1. Participant characteristics, medications and pulmonary function in heart-
failure patients with reduced ejection fraction (HFrEF) and healthy control 
subjects.   
 Control HFrEF P-value 
Demographics 
n 18 22  
Female 5 (28) 6 (27)  
Age, y 58 ± 9 63 ± 8 0.062 
Stature, cm 174 ± 15 175 ± 10 0.754 
Body mass, kg 78.7 ± 15.2 89.9 ± 16.7 0.034 
BMI, kg/m2 25.9 ± 4.4 29.2 ± 4.4 0.020 
BSA, m2 1.95 ± 0.21 2.08 ± 0.23 0.069 
Aetiology, n    10 ISC/12IDC  
HF duration, mo    68 ± 75  
LVEF, %    28.5 ± 7.9  
NYHA functional class        
I    6 (27)  
II    12 (55)  
III    4 (18)  
Medications        
ACE inhibitors    22 (100)  
Aspirin    19 (86)  
ȕ-blockers    21 (95)  
Digitalis    8 (36)  
Diuretics    16 (73)  
Pulmonary function        
FVC, % predicted 103 ± 12 83 ± 15.8 <0.001 
FEV1, % predicted 106 ± 11 81 ± 18 <0.001 
FEV1/FVC, % predicted 97 ± 7 105 ± 19 0.145 
PEF, L/s 98 ± 11 74 ± 22 <0.001 
FEF25-75%, % predicted 125 ± 32 84 ± 24 0.001 
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IC, L 109 ± 11 86 ± 21 0.002 
DLCO/VA 10.9 ± 6.6 6.4 ± 4.6 0.015 
Data are presented as group mean ± SD or n (%). BMI, body mass index; 
BSA, body surface area; ISC, ischemic; IDC, idiopathic dilated cardiomyopathy; 
HFrEF, heart-failure with reduced ejection fraction; LVEF, left ventricular ejection 
fraction; NYHA, New York Heart Association; ACE, angiotensin converting enzyme; 
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; PEF; peak 
expiratory flow rate; FEF25-75%, forced expiratory flow at 25-75% of FVC; IC, 
inspiratory capacity; DLCO, lung diffusing capacity for carbon monoxide; VA, 
alveolar volume. P-values, group mean control vs. group mean HF.     
 
Table 2. Baseline (i.e. pre-albuterol) measures of cardiovascular function, lung 
diffusing capacity and indices of lung fluid balance in heart-failure patients with 
reduced ejection fraction (HFrEF) and healthy control subjects.   
 Control HFrEF P-value 
Cardiovascular function 
Q, L/min 4.14 ± 0.82 3.41 ± 1.33 0.047 
CI, L/min/m2 2.15 ± 0.44 1.63 ± 0.58 0.003 
SV, ml 69.7 ± 21.7 54.5 ± 19.5 0.016 
HR, bpm 61 ± 10 65 ± 9 0.049 
SaO2, % 98.9 ± 1.5 97.8 ± 1.7 0.032 
SBP. mmHg 124 ± 17 120 ± 14 0.389 
DBP, mmHg 78 ± 13 77 ± 11 0.740 
MAP, mmHg 94 ± 11 92 ± 8 0.360 
Lung diffusing capacity 
DLCO, ml/mmHg/min 19.5 ± 3.5 16.0 ± 6.1 0.037 
DLNO, ml/mmHg/min 68.5 ± 15.1 61.4 ± 24.8 0.294 
DmCO, ml/mmHg/min 31.1 ± 6.9 29.7 ± 11.27 0.294 
Vc, ml 81.5 ± 31.1 54.9 ± 22.1 0.003 
DmCO/Vc 0.47 ± 0.26 0.57 ± 0.29 0.264 
Lung fluid balance 
Lung density, HU í867 ± 20 í804 ± 35 <0.001 
Vtis, ml 884 ± 123 998 ± 200 0.041 
EVLW, ml 802 ± 133 943 ± 202 0.015 
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Data are presented as group mean ± SD. Q, cardiac output; CI, cardiac 
index; SV, stroke volume; HR, heart rate; SaO2, arterial oxygen saturation; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; MAP; mean arterial pressure; 
DLCO, lung diffusing capacity for carbon monoxide; DLNO; lung diffusing capacity 
for nitric oxide; DmCO, alveolar-capillary membrane conductance; Vc, pulmonary 
capillary blood volume; Vtis; lung tissue volume; EVLW, extravascular lung water. 
P-values, group mean control vs. group mean HFrEF.     
 
 
 
 
Table 3. Measures of pulmonary function before and after albuterol administration 
in heart-failure patients with reduced ejection fraction (HFrEF) and healthy control 
subjects.   
 Control HFrEF 
 Pre-albuterol Post-albuterol Pre-
albuterol 
Post-
albuterol 
FVC, L 4.5
3 
± 0.7
8 
4.3
8 
± 0.81 3.5
0 
± 1.1
4 
3.3
7 
± 1.11 
FEV1, L 3.6
4 
± 0.6
3 
3.7
0 
± 0.69 2.6
7 
± 1.0
3 
2.7
7 
± 0.99
**
 
FEV1/F
VC, % 
81 ± 6 85 ± 6** 75 ± 11 82 ± 7** 
PEF, L/s 9.1
2 
± 1.6
3 
8.9
7 
± 1.59 6.8
4 
± 2.5
9 
6.9
7 
± 2.87 
FEF25-
75%, L/s 
3.7
3 
± 0.9
3 
4.3
1 
± 1.02
**
 
2.3
5 
± 1.2
8 
2.9
2 
± 1.42
**
 
IC, L 3.3
1 
± 0.6
4 
3.5
1 
± 0.74
**
 
2.6
1 
± 0.8
1 
2.8
3 
± 0.90
*
 
DLCO/
VA 
10.
87 
± 6.6
0 
10.
93 
± 6.83 6.3
7 
± 4.5
6 
6.4
8 
± 3.08 
Data are presented as group mean ± SD. FVC, forced vital capacity; FEV1, forced 
expiratory volume in 1 s; PEF; peak expiratory flow rate; FEF25-75%, forced expiratory 
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flow at 25-75% of FVC; IC, inspiratory capacity; DLCO, lung diffusing capacity for 
carbon monoxide; VA, alveolar volume.  
*P < 0.05 & **P < 0.01, value significantly different vs. pre-albuterol.      
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
